<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2)
NPS Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.001 Par Value
- --------------------------------------------------------------------------------
(Title of Class of Securities)
62936P103
- --------------------------------------------------------------------------------
(CUSIP Number)
Donald F. Parman, SmithKline Beecham Corporation
One Franklin Plaza, Philadelphia, PA 19102
Telephone 215-751-7633
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
November 2, 1998
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.
Check the following box if a fee is being paid with the statement / /. (A fee is
not required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
This Amendment No. 2 amends and supplements the Statement on Schedule 13D
electronically filed on December 15, 1997, and Amendment No. 1 electronically
filed on January 9, 1998 with respect to the ownership of securities of
NPS Pharmaceuticals, Inc.
The undersigned hereby amends and supplements Items 2, 3 and 5 of the Initial
Statement by the following information (capitalized terms used herein without
definition shall have the same meaning as set forth in the Initial Statement).
<PAGE> 2
SCHEDULE 13D
CUSIP NO. 62936P103 PAGE 2 OF 8 PAGES
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
SmithKline Beecham plc
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) /x/
(b) / /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(D) OR 2(E) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
England
- --------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
SHARES -0-
BENEFICIALLY -----------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING
PERSON -----------------------------------------------------------------
WITH 9 SOLE DISPOSITIVE POWER
-0-
-----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
-0-
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* / /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE> 3
SCHEDULE 13D
CUSIP NO. 62936P103 PAGE 3 OF 8 PAGES
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
S.R. One, Limited
23-1729901
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) /x/
(b) / /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(D) OR 2(E) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Pennsylvania Business Trust
- --------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
SHARES 717,601
BENEFICIALLY -----------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING
PERSON -----------------------------------------------------------------
WITH 9 SOLE DISPOSITIVE POWER
717,601
-----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
717,601
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* / /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.74%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
<PAGE> 4
SCHEDULE 13D
CUSIP NO. 62936P103 PAGE 4 OF 8 PAGES
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
SmithKline Beecham Corporation
23-1099050
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) /x/
(b) / /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(D) OR 2(E) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Pennsylvania
- --------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
SHARES 364,000
BENEFICIALLY -----------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING
PERSON -----------------------------------------------------------------
WITH 9 SOLE DISPOSITIVE POWER
364,000
-----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
364,000
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* / /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.91%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE> 5
Page 5 of 8 Pages
Item 1. Security and Issuer.
Item 2. Identity and Background.
(a) In the original Schedule 13D and Amendment No. 1 filings,
SmithKline Beecham plc ("SBplc") was incorrectly identified as the beneficial
owner of shares owned beneficially and of record by its wholly owned subsidiary,
SmithKline Beecham Corporation ("SBCorp"). SBCorp, a company organized under the
laws of Pennsylvania, discovers, develops, manufactures and markets
pharmaceuticals, vaccines, over-the-counter medicines and health-related
products, and provides healthcare services including clinical laboratory
testing, disease management, and pharmaceutical benefit management.
Collectively, SROne and SBCorp are sometimes referred to as the
"Group".
(b) The principal business address for SB Corp is:
One Franklin Plaza
Philadelphia, Pennsylvania 19102
Item 3. Source and Amount of Funds or Other Consideration.
SRO exercised 5,700 stock options for an aggregate consideration of
$12,600. SBCorp acquired 204,000 shares of Common Stock at $8.869 per share in a
private placement for an aggregate consideration of $1,809,276. The source for
funds in each case was Working Capital.
Item 4. Purpose of Transaction.
<PAGE> 6
Page 6 of 8 Pages
Item 5. Interest in Securities of the Issuer.
(a) Amount and Percent Beneficially Owned
Registered Name No. of Shares Percent
SRO 717,601 5.74%
SBCorp 364,000 2.91%
-----
8.65%
(b)
(c) On October 20, 1998, SRO exercised 5,700 stock options granted to
its representative on the Issuer's Board of Directors, 1,200 of which were
purchased at $3.00 per share and 4,500 were purchased at $2.00 per share for an
aggregate amount of $12,600. Pursuant to a Stock Purchase Agreement entered into
in connection with a Collaborative Research and License Agreement between the
Issuer and SBCorp, SBCorp purchased 204,000 shares of Common Stock at $8.869 per
share on November 2, 1998. If the Collaborative Research and License Agreement
remains in full force and effect as of October 31, 1999, SBCorp will purchase
additional shares of Common Stock at market price plus $2.50 per share.
(d)
(e)
Item 6. Contracts, Arrangements, Understandings or
Relationship With respect to Securities of the Issuer.
Item 7. Materials to be Filed as Exhibits.
<PAGE> 7
Page 7 of 8 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, the undersigned certifies that the information set forth in the
Statement is true, correct and complete.
DATED: November 5, 1998
S.R. ONE, LIMITED
By: /s/
Donald F. Parman
Vice President
and Secretary
<PAGE> 8
Page 8 of 8 Pages
EXHIBIT 1
The undersigned hereby agree, pursuant to Rule 13d-1(f)(1) under Section
13(d) of the Securities Exchange Act of 1934, as amended, that (1) they shall
cause a single Schedule 13D to be filed on behalf of both parties in respect of
their ownership interests in the Common Stock of NPS Pharmaceuticals, Inc. and
(2) S.R. One, Limited shall be authorized to sign said Schedule 13D and any
amendments thereto on behalf of both members of the Group.
S.R. ONE, LIMITED
By: /s/
Donald F. Parman
Vice President
and Secretary
SMITHKLINE BEECHAM CORPORATION
By: /s/
Donald F. Parman
Secretary
DATED: November 5, 1998
- ------------------------------
